Reports progress towards global supply chain development and commercial deployment Ended the third quarter of 2023 with cash, cash equivalents, restricted cash and marketable securities of $95.6 million Management to host conference call and webcast Tuesday, November 28, 2023 at 8:30 AM ET Management to host investor day on December […]
Financial
Route 92 Medical Raises Over $31 Million in Oversubscribed Series F Equity Financing to Accelerate its Commercialization into the Rapidly Growing Stroke Treatment Market
SAN MATEO, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) — Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced it has raised over $31 million in a Series F financing to accelerate the commercial adoption of a neurovascular intervention […]
BioSig Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Westport, CT, Nov. 13, 2023 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of 6,996,922 […]
Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update
U.S. FDA granted Investigational Device Exemption (“IDE”) approval to initiate the BACKBEAT pivotal study evaluating AVIM therapy (BackBeat CNT) in hypertensive pacemaker patients BACKBEAT pivotal study on track to start enrollment before the end of 2023, with a mid-2025 target for completion of enrollment Expected operating cash runway sufficient into […]
Pulse Biosciences Reports Business Updates and Third Quarter 2023 Financial Results
HAYWARD, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced financial results for the third quarter ended September 30, 2023. Recent Business Highlights Advanced feasibility and preclinical studies for the cardiac ablation clamp and catheter programs, and expect to file an FDA 510(k) submission for
Centerline Biomedical announces New CFO Indrani Egleston
CLEVELAND, Nov. 13, 2023 /PRNewswire/ — Centerline Biomedical, Inc. (“Centerline”), an innovator in cardiovascular visualization and navigation systems, today announced the appointment of Indrani Egleston to the position of Chief Financial Officer (CFO). Ms. Egleston joins the company…
VentureMed Receives TransitionalPass-through Payment (TPT) for FLEXVessel Prep™ System
MINNEAPOLIS Nov. 8, 2023/PRNewswire/ — VentureMed Group, Inc., a privately held medical device innovator in access management for arteriovenous (AV) fistulas and grafts and vessel preparation for interventional treatment of peripheral arterial disease (PAD) announced today that the Center for Medicare & Medicaid Services (CMS) has granted The FLEX VesselPrep™ […]
Nanox to Report Third Quarter 2023 Financial Results on November 28, 2023 and Reschedules Investor Day for December 4, 2023
NEVE ILAN, Israel, Nov. 09, 2023 (GLOBE NEWSWIRE) — NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter ended September 30, 2023 on November 28, 2023 at 8:30 a.m. ET. The Company […]
BioSig Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Westport, CT, Nov. 09, 2023 (GLOBE NEWSWIRE) — Westport, CT, Nov. 9, 2023 — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced that it has entered into a definitive agreement for the […]
Edgewise Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
BOULDER, Colo.–(BUSINESS WIRE)–Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the third quarter of 2023 and recent business highlights. “I’m thrilled with the progress we’ve made in 2023 across our skeletal and cardiovascular programs,” said Kevin Koch, Ph.D., President and Chief Executive Officer of Edgewise. “Most recently, we started enrolling individuals in two important studies: GRAND CANYON, a global p
